T. Rowe Price Associates
BNTC icon

T. Rowe Price Associates’s Benitec Biopharma BNTC Stock Holding History

T. Rowe Price Associates’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+18,528
New +$220K ﹤0.01% 2926

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

T. Rowe Price Associates's BNTC Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Benitec Biopharma (BNTC) in Q2 2026: 18,528 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #2926 among its holdings.

87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • T. Rowe Price Associates held 18,528 shares of Benitec Biopharma worth $248K as of Q2 2026.
  • Benitec Biopharma was a new T. Rowe Price Associates position in Q2 2026.
  • Benitec Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2926 holding.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.